Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01275 (
glucagon
)
26,492
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
It is known that central injection of
glucagon
-like peptide-1 (GLP-1) suppresses feeding in rats and chicks, but the systems for GLP-1 are still open with special reference to the chick. The present study was done to determine whether a noradrenergic mechanism contributes to the anorexigenic effect of GLP-1 on the neonatal chick. Central administration of norepinephrine (NE) suppressed food intake with
narcolepsy
as GLP-1 in chicks. However, in spite of that dopamine (DA) did not affect food intake, coadministration of inhibitor of dopamine-beta-hydroxylase (DBH), fusaric acid (FA), attenuated the suppressive effect of GLP-1 on feeding behavior. It is suggested that there may be the interactive relationships between GLP-1 and noradrenergic system in the neonatal chick.
...
PMID:Intracerebroventricular injection of fusaric acid attenuates the anorexia by glucagon-like peptide-1 in the neonatal chick. 1170 Nov 95
